ATE507244T1 - Anti-igf-i-rezeptor-antikörper - Google Patents

Anti-igf-i-rezeptor-antikörper

Info

Publication number
ATE507244T1
ATE507244T1 AT03731327T AT03731327T ATE507244T1 AT E507244 T1 ATE507244 T1 AT E507244T1 AT 03731327 T AT03731327 T AT 03731327T AT 03731327 T AT03731327 T AT 03731327T AT E507244 T1 ATE507244 T1 AT E507244T1
Authority
AT
Austria
Prior art keywords
receptor
igf
antibodies
molecules
cancer
Prior art date
Application number
AT03731327T
Other languages
English (en)
Inventor
Rajeeva Singh
Daniel Tavares
Nancy Dagdigian
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29732484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE507244(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunogen Inc filed Critical Immunogen Inc
Application granted granted Critical
Publication of ATE507244T1 publication Critical patent/ATE507244T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03731327T 2002-06-14 2003-06-12 Anti-igf-i-rezeptor-antikörper ATE507244T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/170,390 US7538195B2 (en) 2002-06-14 2002-06-14 Anti-IGF-I receptor antibody
PCT/US2003/016211 WO2003106621A2 (en) 2002-06-14 2003-06-12 Anti-igf-i receptor antibody

Publications (1)

Publication Number Publication Date
ATE507244T1 true ATE507244T1 (de) 2011-05-15

Family

ID=29732484

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03731327T ATE507244T1 (de) 2002-06-14 2003-06-12 Anti-igf-i-rezeptor-antikörper

Country Status (17)

Country Link
US (5) US7538195B2 (de)
EP (1) EP1532174B3 (de)
JP (2) JP4699754B2 (de)
CN (2) CN1678633B (de)
AT (1) ATE507244T1 (de)
AU (1) AU2003241580C1 (de)
BR (1) BR0311792A (de)
CA (1) CA2489440A1 (de)
DE (1) DE60336906D1 (de)
ES (1) ES2365845T7 (de)
IL (1) IL165063A0 (de)
MX (1) MXPA04012392A (de)
NZ (1) NZ536479A (de)
RU (1) RU2421465C2 (de)
SG (1) SG141243A1 (de)
WO (1) WO2003106621A2 (de)
ZA (1) ZA200409022B (de)

Families Citing this family (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
EP2796468A2 (de) 2001-01-05 2014-10-29 Pfizer Inc Antikörper für Insulinähnlichen Wachstumsfaktor-1-Rezeptor
US20080152649A1 (en) * 2002-03-01 2008-06-26 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
US20050276812A1 (en) * 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
NZ571508A (en) * 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
AU2004303792A1 (en) * 2003-12-08 2005-07-07 Immunogen, Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
US7919083B2 (en) * 2002-11-15 2011-04-05 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US7132111B2 (en) * 2003-01-03 2006-11-07 Epien Medical, Inc. Odorless formulation for treating mucosal discontinuities
WO2005016970A2 (en) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
ES2541134T3 (es) * 2003-05-12 2015-07-16 Helion Biotech Aps Anticuerpos de MASP-2
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
DE602004029581D1 (de) 2003-08-13 2010-11-25 Pfizer Prod Inc Modifizierte humane igf-1r antikörper
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
BRPI0506629A (pt) * 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
RU2386638C2 (ru) * 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2006008639A1 (en) * 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
AU2011236042B2 (en) * 2004-07-29 2013-09-05 Pierre Fabre Medicament Novel anti-IGF-IR antibodies and uses thereof
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
PL2343380T3 (pl) 2004-11-16 2020-03-31 Humanigen, Inc. Wymiana kasety dla regionu zmiennego immunoglobuliny
MX2007006640A (es) * 2004-12-03 2007-06-19 Schering Corp Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7524831B2 (en) * 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
AU2006236637B2 (en) * 2005-04-15 2012-09-06 Merck Sharp & Dohme Corp. Methods and compositions for treating or preventing cancer
JP5129122B2 (ja) 2005-04-26 2013-01-23 トリオン ファーマ ゲーエムベーハー 癌治療のための抗体およびグルココルチコイドの組み合わせ
JP5707024B2 (ja) * 2005-05-26 2015-04-22 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤
CN101287761A (zh) * 2005-06-15 2008-10-15 先灵公司 抗-igf1r抗体制剂
PT2100618E (pt) 2005-06-17 2014-04-07 Philadelphia Health & Educatio Um anticorpo anti-pdgfr-alfa para o tratamento de cancro ósseo metastático
WO2007000328A1 (en) * 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
AU2007212447B2 (en) * 2006-02-03 2013-02-21 Imclone Llc IGF-IR antagonists as adjuvants for treatment of prostate cancer
WO2007093008A1 (en) * 2006-02-17 2007-08-23 Adelaide Research & Innovation Pty Ltd Antibodies to insulin-like growth factor i receptor
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
EA018030B1 (ru) * 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
JP5399900B2 (ja) 2006-06-30 2014-01-29 メルク・シャープ・アンド・ドーム・コーポレーション Ｉｇｆｂｐ２インヒビター
NZ574215A (en) 2006-07-18 2012-07-27 Sanofi Aventis Antagonist antibody against epha2 for the treatment of cancer
EP1914242A1 (de) * 2006-10-19 2008-04-23 Sanofi-Aventis Neue Antikörper gegen CD38 zur Behandlung von Krebs
CN102123712B (zh) 2006-12-13 2014-03-19 默沙东公司 使用igf1r抑制剂治疗癌症的方法
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
KR20090114449A (ko) * 2007-02-14 2009-11-03 글락소 그룹 리미티드 Ｉｇｆ-ⅰｒ에 대한 항체
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
WO2008108986A2 (en) * 2007-03-02 2008-09-12 Amgen Inc. Methods and compositions for treating tumor diseases
EP2565207A3 (de) * 2007-03-14 2013-06-12 Alexion Cambridge Corporation Humanisierte Anti-Faktor-B-Antikörper
US8492328B2 (en) 2007-05-17 2013-07-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
EP2197421A1 (de) * 2007-08-31 2010-06-23 Amgen, Inc Protein-formulierung in festem zustand
WO2009043049A2 (en) 2007-09-27 2009-04-02 Amgen Inc. Pharmaceutical formulations
WO2009064838A1 (en) 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
CA2709029A1 (en) 2007-12-21 2009-07-02 Bianca Eser Stability testing of antibodies
HUE035184T2 (en) 2008-03-18 2018-05-02 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
AU2009245792B2 (en) 2008-05-07 2012-11-01 Coimmune, Inc. Humanized antibodies against human interferon-alpha
AR074726A1 (es) 2008-12-12 2011-02-09 Boehringer Ingelheim Int Anticuerpos anti-igf (factor de crecimiento insulinico)
SG173152A1 (en) 2009-02-05 2011-08-29 Immunogen Inc Novel benzodiazepine derivatives
CN102481361B (zh) 2009-04-16 2014-10-22 默沙东公司 用于治疗癌症的组合物和方法
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
AU2010306581B2 (en) * 2009-10-16 2015-03-19 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
MX344382B (es) 2009-10-23 2016-12-14 Amgen Inc * Adaptador de vial y sistema.
EP4406615A3 (de) 2009-10-26 2024-12-11 F. Hoffmann-La Roche AG Verfahren zur herstellung eines glykosylierten immunglobulins
WO2011053779A2 (en) 2009-10-30 2011-05-05 Bristol-Myers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
TWI672318B (zh) 2010-02-24 2019-09-21 美商免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
HUE026173T2 (en) 2010-06-07 2016-05-30 Amgen Inc pharmaceutical Pump
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
EP2670426B1 (de) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodale trail-moleküle und ihre verwendungen in zelltherapien
US20140037642A1 (en) 2011-02-02 2014-02-06 Amgen Inc. Methods and compositions relating to inhibition of igf-1r
KR20190089048A (ko) 2011-02-15 2019-07-29 이뮤노젠 아이엔씨 컨쥬게이트의 제조방법
AU2012236573B2 (en) 2011-03-31 2016-06-02 Amgen Inc. Vial adapter and system
TR201905991T4 (tr) 2011-04-20 2019-05-21 Amgen Inc Oto enjektör aparatı.
US20140309229A1 (en) 2011-10-13 2014-10-16 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
EP3045188B1 (de) 2011-10-14 2020-12-23 Amgen Inc. Injektor und verfahren zur montage
CA2852127C (en) 2011-11-11 2020-10-27 Duke University Combination drug therapy for the treatment of solid tumors
AU2012340766B2 (en) 2011-11-23 2018-05-10 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
WO2013177035A2 (en) 2012-05-24 2013-11-28 Alexion Pharmaceuticals, Inc. Humaneered anti-factor b antibody
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
WO2014018113A1 (en) 2012-07-24 2014-01-30 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
US9605074B2 (en) * 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
PL2890717T3 (pl) 2012-08-31 2020-08-10 Immunogen, Inc. Testy i zestawy diagnostyczne do wykrywania receptora folianu
US20150259430A1 (en) 2012-11-05 2015-09-17 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727941A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Verfahren zur Herstellung multispezifischer Antikörper
EP2922590B1 (de) 2012-11-21 2020-02-05 Amgen Inc. Arzneimittelabgabevorrichtung
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
TWI614041B (zh) 2013-03-15 2018-02-11 安美基公司 用於注射器之匣盒
US10092703B2 (en) 2013-03-15 2018-10-09 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
SG11201507417RA (en) 2013-03-15 2015-10-29 Amgen Inc Body contour adaptable autoinjector device
EP2976117B1 (de) 2013-03-22 2020-12-30 Amgen Inc. Injektor und verfahren zur montage
SG10201710013RA (en) * 2013-08-13 2018-01-30 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
CN105744944B (zh) 2013-09-09 2020-07-07 卡尼姆盖德治疗学公司 免疫系统调节器
EP3957345B1 (de) 2013-10-24 2025-12-10 Amgen Inc. Arzneimittelabgabesystem mit temperaturempfindlicher steuerung
CA2920894C (en) 2013-10-24 2023-03-14 Amgen Inc. Injector and method of assembly
MX2016009653A (es) * 2014-01-24 2017-03-27 Henry M Jackson Found Advancement Military Medicine Inc Anticuerpos contra glicoproteina f de virus hendra y nipah.
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
MA39821B1 (fr) 2014-04-08 2020-09-30 Boston Pharmaceuticals Inc Molécules de liaison spécifiques de l'il-21 et leurs utilisations
ES2819863T3 (es) 2014-04-11 2021-04-19 Medimmune Llc Anticuerpos contra HER2 biespecíficos
MX388536B (es) 2014-05-07 2025-03-20 Amgen Inc Autoinyector con elementos reductores del shock.
CN106470717B (zh) 2014-06-03 2020-09-11 安姆根有限公司 药物递送系统和使用方法
AU2015332557B2 (en) 2014-10-14 2020-05-14 Amgen Inc. Drug injection device with visual and audio indicators
MX385320B (es) 2014-11-10 2025-03-18 Medimmune Ltd Moléculas de unión específicas para grupo de diferenciación 73 (cd73) y usos de las mismas.
WO2016075176A1 (en) 2014-11-11 2016-05-19 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
EP3848072A1 (de) 2014-12-19 2021-07-14 Amgen Inc. Medikamentenabgabevorrichtung mit näherungssensor
ES2785311T3 (es) 2014-12-19 2020-10-06 Amgen Inc Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
CA3069716C (en) 2015-02-17 2021-11-09 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (de) 2015-02-27 2021-12-15 Amgen Inc. Arzneimittelabgabevorrichtung mit nadelschutzmechanismus mit abstimmbarem widerstandsschwellwert gegenüber der bewegung des nadelschutzes
WO2016144650A1 (en) 2015-03-06 2016-09-15 Canimguide Therapeutics Ab Immune system modulators and compositions
EP3842459A1 (de) 2015-06-29 2021-06-30 ImmunoGen, Inc. Anti-cd123-antikörper und konjugate und derivate davon
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
SG10202103712VA (en) 2015-11-10 2021-05-28 Medimmune Llc Binding molecules specific for asct2 and uses thereof
WO2017100501A1 (en) 2015-12-09 2017-06-15 Amgen Inc. Auto-injector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
HRP20241557T1 (hr) 2016-03-10 2025-05-23 Acceleron Pharma Inc. Proteini koji vezuju receptor aktivina tipa 2 i njihova uporaba
KR101783907B1 (ko) * 2016-03-15 2017-10-10 다이노나(주) ＣＤ66ｃ에 대한 항체와 화학치료제를 포함하는 폐암 예방 또는 치료용 약학조성물
WO2017160799A1 (en) 2016-03-15 2017-09-21 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
CA3018272A1 (en) 2016-04-22 2017-10-26 Acceleron Pharma Inc. Alk7 binding proteins and uses thereof
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
AU2017263558B2 (en) 2016-05-13 2022-12-22 Amgen Inc. Vial sleeve assembly
EP3458988B1 (de) 2016-05-16 2023-10-18 Amgen Inc. Datenverschlüsselung in medizinischen vorrichtungen mit eingeschränkter rechenfähigkeit
SG10202001787QA (en) 2016-06-02 2020-04-29 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
JP7227146B2 (ja) 2016-11-23 2023-02-21 バイオベラティブ セラピューティクス インコーポレイテッド 凝固第ｉｘ因子および凝固第ｘ因子に結合する二重特異性抗体
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
JP2020503976A (ja) 2017-01-17 2020-02-06 アムジエン・インコーポレーテツド 注入デバイスならびに関連する使用および組立方法
MX2019009625A (es) 2017-02-17 2019-10-09 Amgen Inc Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
EP3582829A1 (de) 2017-02-17 2019-12-25 Amgen Inc. Einführmechanismus für eine arzneimittelabgabevorrichtung
EP3592403B1 (de) 2017-03-06 2025-08-20 Amgen Inc. Wirkstofffreisetzungsvorrichtung mit aktivierungsverhinderungsfunktion
CA3052482A1 (en) 2017-03-07 2018-09-13 Amgen Inc. Needle insertion by overpressure
AU2018230486B2 (en) 2017-03-09 2023-05-11 Amgen Inc. Insertion mechanism for drug delivery device
CN118743804A (zh) 2017-03-28 2024-10-08 美国安进公司 柱塞杆和注射器组件系统以及方法
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
AU2018288604B2 (en) 2017-06-22 2023-12-21 Amgen Inc. Device activation impact/shock reduction
MA49461A (fr) 2017-06-23 2020-04-29 Amgen Inc Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
US11672733B2 (en) 2017-07-21 2023-06-13 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
US11484648B2 (en) 2017-07-25 2022-11-01 Amgen Inc. Drug delivery device with container access system and related method of assembly
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
ES2939292T3 (es) 2017-10-04 2023-04-20 Amgen Inc Adaptador de flujo para dispositivo de administración de fármacos
EP4257164A3 (de) 2017-10-06 2024-01-17 Amgen Inc. Arzneimittelabgabevorrichtung mit verriegelungsvorrichtung und zugehöriges montageverfahren
EP3694578B1 (de) 2017-10-09 2025-09-24 Amgen Inc. Arzneimittelabgabevorrichtung mit antriebsanordnung sowie zugehöriges verfahren zur montage
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
MA50528A (fr) 2017-11-03 2020-09-09 Amgen Inc Systèmes et approches pour stériliser un dispositif d'administration de médicament
WO2019089178A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
US12053618B2 (en) 2017-11-06 2024-08-06 Amgen Inc. Fill-finish assemblies and related methods
IL319987A (en) 2017-11-10 2025-06-01 Amgen Inc Plungers for drug delivery devices
SG11202003004RA (en) 2017-11-16 2020-04-29 Amgen Inc Door latch mechanism for drug delivery device
JP7747438B2 (ja) 2017-11-16 2025-10-01 アムジエン・インコーポレーテツド 失速及び終点検出を有するオートインジェクタ
CA3091184A1 (en) 2018-02-14 2019-08-22 Viela Bio, Inc. Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
MX2021000749A (es) 2018-07-24 2021-03-29 Amgen Inc Dispositivos de suministro para administrar farmacos.
US12115360B2 (en) 2018-07-24 2024-10-15 Amgen Inc. Hybrid drug delivery devices with grip portion
US12042645B2 (en) 2018-07-24 2024-07-23 Amgen Inc. Delivery devices for administering drugs
EP3829692A1 (de) 2018-07-31 2021-06-09 Amgen Inc. Flüssigkeitsweganordnungen für wirkstofffreisetzungsvorrichtung
US20210346601A1 (en) 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
EP3856283A1 (de) 2018-09-28 2021-08-04 Amgen Inc. Anordnung zur aktivierung des muskeldrahtvorschubs für eine medikamentenabgabevorrichtung
AU2019352616B2 (en) 2018-10-02 2024-10-10 Amgen Inc. Injection systems for drug delivery with internal force transmission
US12151089B2 (en) 2018-10-05 2024-11-26 Amgen Inc. Drug delivery device having dose indicator
SG11202103800RA (en) 2018-10-15 2021-05-28 Amgen Inc Drug delivery device having damping mechanism
JP2022504805A (ja) 2018-10-15 2022-01-13 アムジエン・インコーポレーテツド 薬物送達デバイスのプラットフォーム式組み立てプロセス
TWI897855B (zh) 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
AU2019370159B2 (en) 2018-11-01 2025-05-29 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
JP7463366B2 (ja) 2018-11-20 2024-04-08 タケダ ワクチン，インコーポレイテッド 新規の抗ジカウイルス抗体及びその使用
AU2019393487A1 (en) * 2018-12-03 2021-06-03 Teijin Pharma Limited Anti-IGF-I receptor humanized antibody
JP7510952B2 (ja) 2019-04-24 2024-07-04 アムジエン・インコーポレーテツド シリンジ滅菌確認アセンブリ及び方法
JP7608439B2 (ja) 2019-08-23 2025-01-06 アムジエン・インコーポレーテツド 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
IL296519A (en) * 2020-06-02 2022-11-01 Teijin Pharma Ltd Anti-igf-1 receptor humanized antibody
US11795225B2 (en) 2020-09-11 2023-10-24 Medimmune Limited Therapeutic binding molecules
EP4211663B1 (de) 2020-09-12 2026-02-18 MedImmune Limited Bewertungsverfahren für eine anti-b7h4-antikörper-wirkstoff-konjugattherapie
CR20230204A (es) * 2020-10-14 2023-10-11 Viridian Therapeutics Inc Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
TW202246339A (zh) * 2021-03-03 2022-12-01 愛爾蘭商赫萊森治療愛爾蘭公司 治療甲狀腺眼疾的方法
CR20230488A (es) 2021-03-18 2023-12-12 Medimmune Ltd Moléculas de unión terapéuticas
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
CA3217207A1 (en) 2021-05-21 2022-11-24 Amgen Inc. Method of optimizing a filling recipe for a drug container
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
TW202320850A (zh) 2021-08-10 2023-06-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法
CA3231484A1 (en) * 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
IT202200003758A1 (it) * 2022-03-01 2023-09-01 Irccs Ospedale Policlinico San Martino Coniugati farmacologici nella terapia del cancro.
CN119630428A (zh) 2022-07-12 2025-03-14 西托姆克斯治疗公司 Epcam免疫缀合物及其用途
CN120659814A (zh) 2023-02-13 2025-09-16 浙江大学绍兴研究院 双特异性抗体及其应用
AU2024318876A1 (en) 2023-07-31 2026-03-19 Astrazeneca Ab Cd123 antibody-drug conjugates and methods of using the same
WO2025151502A1 (en) * 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Modified antibodies
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US553010A (en) * 1896-01-14 Device for holding tools while being ground or sharpened
JPS6330072A (ja) 1986-07-24 1988-02-08 Hitachi Ltd 水平ダイナミツクフオ−カス回路
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
PT98805B (pt) 1990-08-28 1999-01-29 Chiron Corp Processo de preparacao de uma nova proteina de ligacao ao factor de crescimento semelhante a insulina (igfbp-4)
DE4203545A1 (de) * 1992-02-07 1993-08-12 Behringwerke Ag Spezifische antikoerper gegen aktivierte plaettchen, ihre herstellung und ihre verwendung in diagnose und therapie
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5804187A (en) * 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
GB9525180D0 (en) 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
JP2000014383A (ja) 1998-07-03 2000-01-18 Igaku Seibutsugaku Kenkyusho:Kk ヒト化抗体
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US20030236190A1 (en) 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
CA2351452A1 (en) 1998-12-04 2000-06-15 Novartis Ag Methods and compositions useful for targeting activated vitronectin receptor .alpha.v.beta.3
US6696620B2 (en) 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
US20030165502A1 (en) 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
EP2796468A2 (de) * 2001-01-05 2014-10-29 Pfizer Inc Antikörper für Insulinähnlichen Wachstumsfaktor-1-Rezeptor
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
EP1806364B1 (de) 2002-01-18 2013-07-31 Pierre Fabre Medicament Neuartige Anti-IGF-IR-Antikörper und ihre Anwendungen
NZ571508A (en) 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
CA2514231A1 (en) 2003-02-13 2004-08-26 Pfizer Products Inc. Uses of anti-insulin-like growth factor i receptor antibodies
CA2518980A1 (en) 2003-03-14 2004-09-30 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
JP5089582B2 (ja) * 2005-06-07 2012-12-05 エスバテック、アン アルコン バイオメディカル リサーチ ユニット、エルエルシー ＴＮＦαを阻害する安定な可溶性抗体

Also Published As

Publication number Publication date
AU2003241580C1 (en) 2012-07-19
HK1073470A1 (en) 2005-10-07
US20130295050A1 (en) 2013-11-07
RU2421465C2 (ru) 2011-06-20
AU2003241580B2 (en) 2009-11-19
CN101693742A (zh) 2010-04-14
BR0311792A (pt) 2005-06-07
EP1532174A2 (de) 2005-05-25
CN1678633B (zh) 2012-08-29
NZ536479A (en) 2008-06-30
IL165063A0 (en) 2005-12-18
JP4699754B2 (ja) 2011-06-15
WO2003106621A2 (en) 2003-12-24
MXPA04012392A (es) 2005-06-17
SG141243A1 (en) 2008-04-28
ES2365845T3 (es) 2011-10-11
US7985842B2 (en) 2011-07-26
AU2003241580A1 (en) 2003-12-31
US20100009439A1 (en) 2010-01-14
CN101693742B (zh) 2013-02-13
WO2003106621A3 (en) 2004-09-23
EP1532174B3 (de) 2012-12-26
DE60336906D1 (de) 2011-06-09
US7538195B2 (en) 2009-05-26
JP2011041564A (ja) 2011-03-03
RU2004136981A (ru) 2005-08-10
US20090162284A1 (en) 2009-06-25
JP2005533493A (ja) 2005-11-10
US20090155165A1 (en) 2009-06-18
CA2489440A1 (en) 2003-12-24
EP1532174A4 (de) 2005-08-10
EP1532174B1 (de) 2011-04-27
US20030235582A1 (en) 2003-12-25
ZA200409022B (en) 2008-08-27
CN1678633A (zh) 2005-10-05
US8268617B2 (en) 2012-09-18
ES2365845T7 (es) 2013-04-24

Similar Documents

Publication Publication Date Title
DE60336906D1 (de) Anti-igf-i-rezeptor-antikörper
EA200970130A1 (ru) Антагонистическое антитело для лечения рака
Kim et al. Redirection of genetically engineered CAR-T cells using bifunctional small molecules
JP2021166522A (ja) キメラ抗原受容体組成物
Goetz et al. In vivo molecular imaging with cetuximab, an anti-EGFR antibody, for prediction of response in xenograft models of human colorectal cancer
JO3486B1 (ar) اتحادات مناعية مضادة للميزوثيلين واستخداماتها
WO2006099141A3 (en) Anti-mesothelin antibodies
ZA202006504B (en) Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
WO2007149948A3 (en) Compositions and methods for diagnosis and treatment of tumors
Ren et al. Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer
Larose et al. Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing
PH12021552379A1 (en) Anti-egfrviii antibodies and antigen-binding fragments thereof
Alagaratnam et al. Mechano-growth factor expression in colorectal cancer investigated with fluorescent gold nanoparticles
EA200601405A1 (ru) Гуманизированное антитело
EA200600931A1 (ru) Антитело против igf-i-рецептора
DE69829001D1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72
Yao et al. 1163 A novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, BCG033, demonstrates preclinical efficacy against triple-negative breast cancer xenografts
Chizari et al. A Review on the Role of the Different Types of Immunotoxins in the Treatment of Prostate Cancer
Thisted et al. CAR-T cell therapies targeting aspartyl β-hydroxylase (ASPH)
Iyengar et al. Abstract P2-16-07: Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data
Kuntanapreeda et al. The Correlation between HER-2/neu Overexpression and Prognostic and Predictive Factor in Primary Breast Cancer
BR9815775A (pt) Anticorpos monoclonais anti-antìgeno carcinoembriÈnico (cea) humanizados de elevada afinidade
Schrohl et al. Abstract P4-08-08: Cross Reactivity of Clinically Validated Anti-HER2 Antibodies
Padmanaban et al. Abstract A47: IL-4 receptor-targeted delivery of liposomal doxorubicin and siRNA to tumor
UA109423C2 (uk) Композиція та спосіб для діагностики і лікування пухлини

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties